Alliance pharmaceutique pancanadienne (APP) – dernières mises à jour

État Nombre total Résumé
En négociation 40 Non liées à l’oncologie : 27
Liées à l’oncologie : 13
Négociations envisagées 20 Non liées à l’oncologie : 11
Liées à l’oncologie : 9
Négociations terminées 915 Avec lettre d’intention : 790
Sans entente : 125
Négociations qui n’ont pas eu lieu 113

Activités de l’APP dans les quatre dernières semaines

Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.

Lettres d’engagement transmises au cours des quatre dernières semaines

Marque Fabricant Indication Date d’engagement
Braftovi Pfizer Canada ULC in combination with cetuximab and chemotherapy, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test.
Welireg Merck Canada Inc. For the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
Qalsody Biogen Canada Inc. Amyotrophic Lateral Sclerosis (ALS)

Négociations achevées dans les quatre dernières semaines avec une lettre d’intention

Marque Fabricant Indication Date d’engagement Date d’achèvement
Imfinzi-Imjudo AstraZeneca Canada Inc. In combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Imfinzi AstraZeneca Canada Inc. For the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
Imfinzi AstraZeneca Canada Inc. in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment
Imfinzi AstraZeneca Canada Inc. Treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by adjuvant IMFINZI monotherapy treatment after radical cystectomy.
Verzenio Eli Lilly Canada Inc. For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer as follows: • in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy. • in combination with fulvestrant in women with disea
Verzenio Eli Lilly Canada Inc. For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) in postmenopausal women as initial endocrine-based therapy.
Calquence AstraZeneca Canada Inc. In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated MCL who are ineligible for autologous stem cell transplant.
Calquence AstraZeneca Canada Inc. Indicated in combination with venetoclax for the treatment of patients with previously untreated CLL.
Imbruvica Janssen Inc. Venclexta, in combination with ibrutinib, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma
Venclexta AbbVie Corporation Calquence, in combination with venetoclex, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL)
Venclexta AbbVie Corporation In combination with ibrutinib, is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Darzalex SC Janssen Inc. in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant.

Négociations achevées dans les quatre dernières semaines sans entente

Marque Fabricant Indication Date d’engagement Date d’achèvement
Sogroya Novo Nordisk Canada Inc. Growth hormone deficiency

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines

Marque Fabricant Indication Aucune date de négociation

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines